<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Neurology</journal-id>
      <journal-id journal-id-type="iso-abbrev">Neurology</journal-id>
      <journal-id journal-id-type="hwp">neurology</journal-id>
      <journal-id journal-id-type="publisher-id">neur</journal-id>
      <journal-id journal-id-type="pmc">neurology</journal-id>
      <journal-id journal-id-type="publisher-id">NEUROLOGY</journal-id>
      <journal-title-group>
        <journal-title>Neurology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0028-3878</issn>
      <issn pub-type="epub">1526-632X</issn>
      <publisher>
        <publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>
        <publisher-loc>Hagerstown, MD</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24363135</article-id>
      <article-id pub-id-type="pmc">3917681</article-id>
      <article-id pub-id-type="publisher-id">NEUROLOGY2013538892</article-id>
      <article-id pub-id-type="doi">10.1212/WNL.0000000000000090</article-id>
      <article-categories>
        <subj-group subj-group-type="hwp-journal-coll">
          <subject>29</subject>
          <subject>120</subject>
          <subject>178</subject>
          <subject>200</subject>
        </subj-group>
        <subj-group subj-group-type="heading">
          <subject>Clinical/Scientific Notes</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Progressive hemiparesis (Mills syndrome) with aphasia in amyotrophic lateral sclerosis</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>B&#xE4;umer</surname>
            <given-names>Dirk</given-names>
          </name>
          <degrees>DPhil</degrees>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for Travel or Speaker Honoraria:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other Activities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>(1) Oxfordshire Health Services Research Committee (OHSRC/BRC/ NOHF/OUCAGS Junior Research Fellowship Grant Ref:U)</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Butterworth</surname>
            <given-names>Richard</given-names>
          </name>
          <degrees>MD</degrees>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for Travel or Speaker Honoraria:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other Activities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Menke</surname>
            <given-names>Ricarda A.L.</given-names>
          </name>
          <degrees>PhD</degrees>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for Travel or Speaker Honoraria:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>Frontiers in Neuropsychiatric Imaging and Stimulation, Review Editor, 2013</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other Activities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>1) Parkinson&#xEF;&#xBF;&#xBD;s UK (Monument Discovery award), 2) Thames Valley DeNDRoN (Dementias and Neurodegenerative Diseases Research Network) (Research Capability Funding)</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Talbot</surname>
            <given-names>Kevin</given-names>
          </name>
          <degrees>DPhil</degrees>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>Agenzia di Ricerca per la Sclerosi Laterale Amiotrofica (AriSLA), 2009-2012</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for Travel or Speaker Honoraria:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>(1) Neuropathology and Applied Neurobiology, Editorial Board; (2) Journal of Neurology, Neurosurgery and Psychiatry, Editorial Board</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>(1) Medicine at a Glance (Blackwell Science, 2002-present); (2) Motor Neuron Disaese: The Facts (Oxford University Press, 2009-present); (3) Oxford Care Manual of Motor Neuron Disease (Oxford University Press, 2010-present)</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>Avanir Pharmaceuticals 2011-13 UCB Pharma 2012</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other Activities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>Motor Neuron Disease Association (UK) Spinal Muscular Atrophy Europe Patrick Berthould Charitable Trust Parkinson's UK Association Francaise Contre les Myopathies (AFM)</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hofer</surname>
            <given-names>Monika</given-names>
          </name>
          <degrees>FRCPath</degrees>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for Travel or Speaker Honoraria:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other Activities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Turner</surname>
            <given-names>Martin R.</given-names>
          </name>
          <degrees>PhD</degrees>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>(1) Non-profit entity. Serve on the Biomedical Research Advisory Panel to the Motor Neurone Disease Association UK (2) Non-profit entity. Serve as scientific advisor to Ontario Brain Institute</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for Travel or Speaker Honoraria:</title>
                <list-item>
                  <p>(1) Charity. Motor Neurone Disease Association UK paid economy flight and accommodation to attend 22nd International Symposium on ALS in Sydney as plenary speaker. Costs &#x223C;&#xEF;&#xBF;&#xBD;2000. (2) Commercial entity. Accepted hotel accommodation from Sanofi-Aventis for presentation on ALS biomarkers to Brisbane neurologists Nov 2011. Costs &#x223C;AUD200. (3) Charity. ALS Association paid economy flight and accommodation to attend Drug Discovery Workshop on ALS in Washington as speaker. Costs &#x223C;&#xEF;&#xBF;&#xBD;2000. (4) Charity. North-East ALS Consortium. Economy flight and accommodation to speak at annual meeting in Tampa, Florida. Costs &#x223C;&#xEF;&#xBF;&#xBD;1500. (5) Charity. Association of British Neurologists paid economy flight and accommodation to speak at Sri Lankan Neurologists' Association meeting in Colombo. Costs &#x223C;&#xEF;&#xBF;&#xBD;1500. (6) Commercial entity. Cytokinetics Inc. Economy train fare and accommodation to attend CY4026 Investigators' meeting in Paris, France. Costs &#x223C;&#xEF;&#xBF;&#xBD;500. (7) Charity. ALS Association. Economy flight and accommodation to speak at Cold Spring Harbor laboratory meeting on ALS. Costs &#x223C;&#xEF;&#xBF;&#xBD;1000. (8) Non-profit entity. University of Ontario. Economy flight and accommodation to speak at ALS-FTD meeting. Costs &#x223C;&#xEF;&#xBF;&#xBD;1500. (9) Non-profit entity. University of Hannover. Economy flight and accommodation to speak on ALS at Neurological Institute.</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>(1) The Brain - A Beginner's Guide, Oneworld, 2008 (2) Motor Neuron Disease - A Care Manual, Oxford University Press, 2010</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>(1) Non-profit entity. Medical Research Council Clinician Scientist Fellowship 2008-2013, G0701923, &#xEF;&#xBF;&#xBD;966,732</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>(1) Commercial. Biogen Idec on ALS staging. &#xEF;&#xBF;&#xBD;3000 (2) Non-profit. University of Michigan. Grant review. &#xEF;&#xBF;&#xBD;300 (3) Non-profit. University of Ontario. Grant review. &#xEF;&#xBF;&#xBD;300</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other Activities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>(1) Non-profit entity. Medical Research Council/EU Joint Programme in Neurodegenerative Disease Research 2012-15, MR/K000780/1, &#xEF;&#xBF;&#xBD;73,102 (2) Non-profit entity. Thierry Latran Foundation Grant Award 2012-14, &#xEF;&#xBF;&#xBD;100,100</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <aff>From Oxford University, John Radcliffe Hospital (D.B., R.A.L.M., K.T., M.H., M.R.T.); Milton Keynes Hospital NHS Trust (R.B.), Buckinghamshire; and Oxford University, Warneford Hospital (R.A.L.M.), UK.</aff>
      </contrib-group>
      <author-notes>
        <corresp>Correspondence to Dr. Turner: <email>martin.turner@ndcn.ox.ac.uk</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <day>4</day>
        <month>2</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>4</day>
        <month>2</month>
        <year>2014</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="ppub"/>. -->
      <volume>82</volume>
      <issue>5</issue>
      <fpage>457</fpage>
      <lpage>458</lpage>
      <history>
        <date date-type="received">
          <day>21</day>
          <month>7</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>16</day>
          <month>9</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2014 American Academy of Neurology</copyright-statement>
        <copyright-year>2014</copyright-year>
        <copyright-holder>American Academy of Neurology</copyright-holder>
        <license license-type="open-access">
          <license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri xlink:title="pdf" xlink:type="simple" xlink:href="NEUROLOGY2013538892.pdf"/>
      <abstract abstract-type="excerpt">
        <p>The onset of motor symptoms in amyotrophic lateral sclerosis (ALS) is strikingly focal. In three-quarters of cases, weakness emerges unilaterally in one limb, typically spreading contiguously over months to become bilateral.<sup>1</sup> An extremely rare clinical syndrome of upper motor neuron&#x2013;predominant, progressive hemiparesis was first described by American neurologist Charles Karsner Mills (1845&#x2013;1930).<sup>2</sup> More typical ALS shares a common histopathologic signature with frontotemporal dementia (FTD), consisting of ubiquitinated neuronal and glial inclusions containing the DNA and RNA binding protein, TDP-43. Cognitive impairment may be detected in at least one-third of ALS cases and involves mainly deficits in language, executive function, and fluency, with variable levels of behavioral impairments that all have overlap with the purer FTD syndromes. Frank FTD is seen in up to 15% of patients with ALS, in whom it typically occurs before or soon after the development of motor symptoms, and is associated with a more rapid disease progression.<sup>3</sup></p>
      </abstract>
      <custom-meta-group>
        <custom-meta>
          <meta-name>OPEN-ACCESS</meta-name>
          <meta-value>TRUE</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <p>The onset of motor symptoms in amyotrophic lateral sclerosis (ALS) is strikingly focal. In three-quarters of cases, weakness emerges unilaterally in one limb, typically spreading contiguously over months to become bilateral.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> An extremely rare clinical syndrome of upper motor neuron&#x2013;predominant, progressive hemiparesis was first described by American neurologist Charles Karsner Mills (1845&#x2013;1930).<sup><xref rid="R2" ref-type="bibr">2</xref></sup> More typical ALS shares a common histopathologic signature with frontotemporal dementia (FTD), consisting of ubiquitinated neuronal and glial inclusions containing the DNA and RNA binding protein TDP-43. Cognitive impairment may be detected in at least one-third of ALS cases and involves mainly deficits in language, executive function, and fluency, with variable levels of behavioral impairments that all have overlap with the purer FTD syndromes. Frank FTD is seen in up to 15% of patients with ALS, in whom it typically occurs before or soon after the development of motor symptoms and is associated with a more rapid disease progression.<sup><xref rid="R3" ref-type="bibr">3</xref></sup></p>
    <sec disp-level="2" id="s1-1">
      <title>Case report.</title>
      <p>A 72-year-old right-handed man reported a 1-year history of progressively worsening speech difficulties and right-sided limb weakness. Bedside examination revealed adequate comprehension but a profound inability to generate speech (in the absence of obvious corticobulbar signs or apraxia), accompanied by a spastic right-sided hemiparesis affecting leg, arm, and face. MRI revealed marked atrophy of the left temporal lobe (<xref ref-type="fig" rid="F1">figure, A</xref>). Over the subsequent months, he developed additional severe bulbar dysfunction with visible tongue wasting, and he died within 1 year of respiratory failure. Postmortem examination (tissue donated to the Thomas Willis Oxford Brain Collection) revealed striking left hemisphere atrophy involving the primary motor cortex and the frontal and particularly the left temporal lobe, accompanied by neuronal loss, gliosis, and TDP-43-positive neuronal and glial cytoplasmic inclusions. Bunina bodies, eosinophilic neuronal inclusions pathognomonic for ALS, were present in the medulla. The predominant right-sided hemiparesis was mirrored at the level of the spinal cord by asymmetric pallor of the corresponding crossed lateral corticospinal tract (<xref ref-type="fig" rid="F1">figure, B</xref>), with marked microglial activation in both the crossed left hemisphere lateral corticospinal tract and the uncrossed anterior corticospinal tract (<xref ref-type="fig" rid="F1">figure, D</xref>).</p>
      <fig id="F1" position="float">
        <label>Figure</label>
        <caption>
          <title>MRI and histologic correlates of a case of amyotrophic lateral sclerosis with progressive aphasia and right hemiparesis</title>
          <p>(A) A 3D-rendered volumetric T1-weighted MRI of the brain (underside shown) demonstrates marked left temporal lobe (arrowhead) atrophy. (B) Luxol fast blue/Cresyl violet staining of the spinal cord section demonstrates greater pallor in the right (crossed) lateral corticospinal tract (arrow). (C) Reconstruction, using diffusion tensor tractography, of the temporal lobe white matter projection tracts, using each hippocampus as the seed-base. This demonstrates reduced left-sided (blue) compared to right-sided (red) connectivity (tracts shown within superior oblique cut-out brain section viewed from left). (D) CD68 immunohistochemistry of the spinal cord section shows intense microglial activation of the right (crossed) corticospinal tract (full arrow) but also the uncrossed anterior corticospinal tract (arrowhead only). Scale bars = 700 &#xB5;m.</p>
        </caption>
        <graphic xlink:href="NEUROLOGY2013538892FF1"/>
      </fig>
    </sec>
    <sec disp-level="2" id="s1-2">
      <title>Discussion.</title>
      <p>The Mills phenotype is extremely uncommon and typically more slowly progressive than this case,<sup><xref rid="R4" ref-type="bibr">4</xref></sup> which was more in keeping with aggressive forms of classical, generalized ALS. Slow progression and aphasia, isolated for several years before the onset of more generalized frontotemporal dementia, has been long recognized.<sup><xref rid="R5" ref-type="bibr">5</xref></sup> Progressive hemiparesis has also been noted in the setting of frontal lobe degeneration.<sup><xref rid="R6" ref-type="bibr">6</xref></sup> Cases of ALS with progressive aphasia<sup><xref rid="R7" ref-type="bibr">7</xref></sup> and semantic dementia<sup><xref rid="R8" ref-type="bibr">8</xref></sup> have been reported, but are exceptional. The effortful speech pattern of our patient was in keeping with nonfluent progressive aphasia, while the pattern of temporal lobe atrophy is usually associated with the fluent, semantic variant. While semantic deficits may well have been present in our patient, the profound temporal atrophy might reflect more complex and widespread disruption of left hemisphere perisylvian networks manifest in the striking asymmetry of the corticospinal tract degeneration observed. Reconstruction of the temporal lobe white matter tract projections using diffusion tensor tractography confirmed reduced connectivity on the left (<xref ref-type="fig" rid="F1">figure, C</xref>; imaging carried out with informed consent as part of The Oxford Study for Biomarkers in MND, approved by the South Central Oxford Research Ethics Committee&#x2014;08/H0605/85).</p>
      <p>A PET study in 2 patients with lateralized motor cortical degeneration syndromes (1 with Mills syndrome) demonstrated strikingly lateralized microglial activation in the hemisphere contralateral to the weakness.<sup><xref rid="R9" ref-type="bibr">9</xref></sup> In our case, CD68 staining for microglia was the most sensitive marker of axonal loss in the main crossed lateral corticospinal tract but also the anterior corticospinal tract carrying uncrossed descending fibers from the cortex to the cervical and thoracic spinal cord. The involvement of the anterior corticospinal tract in ALS has not been systematically studied or specifically highlighted before, and this clear demonstration of its pathologic involvement appears to support the wider concept of cortical dying-forward in contrast to the dogma of solely peripheral neuromuscular dying-back neurodegeneration.</p>
      <p>The co-occurrence of aphasia and progressive right hemiparesis in ALS is exceedingly rare. This case further underscores the need to understand the fundamental basis for the marked clinical heterogeneity of ALS. There was no obvious abnormality of the corpus callosum in our case to explain the striking hemisphere bias to the phenotype. Nonetheless, we speculate that there are specific architectural properties of the interconnected motor and frontotemporal cerebral networks, and possibly their glial milieu, which influence both variable phenotype and speed of progression in ALS.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="other">
        <p>Author contributions: D.B. conceptualized the study, analyzed and interpreted data, and drafted the manuscript. R.B. interpreted the data and edited the manuscript. R.A.L.M. analyzed and interpreted data and edited the manuscript. K.T. interpreted data and edited the manuscript. M.H. analyzed and interpreted data and edited the manuscript. M.R.T. conceptualized the study, analyzed and interpreted data, and drafted the manuscript.</p>
      </fn>
      <fn fn-type="financial-disclosure">
        <p>Study funding: No targeted funding reported.</p>
      </fn>
      <fn fn-type="financial-disclosure">
        <p><italic>Disclosures: D. B&#xE4;umer is funded by an OHSRC/BRC/NOHF Fellowship Grant. R. Butterworth and R. Menke report no disclosures. K. Talbot is Director of The Oxford Motor Neuron Disease Care &amp; Research Centre, which receives funding from the Motor Neurone Disease Association UK Care Centre Program. M. Hofer reports no disclosures. M. Turner is funded by the Medical Research Council/Motor Neurone Disease Association Lady Edith Wolfson Fellowship, and is Co-Director of The Oxford Motor Neuron Disease Care &amp; Research Centre, which receives funding from the Motor Neurone Disease Association UK Care Centre Program. Go to</italic>
<ext-link ext-link-type="uri" xlink:href="http://neurology.org/"><italic>Neurology.org</italic></ext-link>
<italic>for full disclosures.</italic></p>
      </fn>
    </fn-group>
    <ref-list>
      <ref id="R1">
        <label>1.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravits</surname><given-names>JM</given-names></name><name><surname>La Spada</surname><given-names>AR</given-names></name></person-group>
<article-title>ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration</article-title>. <source>Neurology</source>
<year>2009</year>;<volume>73</volume>:<fpage>805</fpage>&#x2013;<lpage>811</lpage><pub-id pub-id-type="pmid">19738176</pub-id></mixed-citation>
      </ref>
      <ref id="R2">
        <label>2.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>CK</given-names></name></person-group>
<article-title>A case of unilateral progressive ascending paralysis, probably representing a new form of degenerative disease</article-title>. <source>J Nerv Ment Dis</source>
<year>1900</year>;<volume>27</volume>:<fpage>195</fpage>&#x2013;<lpage>200</lpage></mixed-citation>
      </ref>
      <ref id="R3">
        <label>3.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elamin</surname><given-names>M</given-names></name><name><surname>Phukan</surname><given-names>J</given-names></name><name><surname>Bede</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia</article-title>. <source>Neurology</source>
<year>2011</year>;<volume>76</volume>:<fpage>1263</fpage>&#x2013;<lpage>1269</lpage><pub-id pub-id-type="pmid">21464431</pub-id></mixed-citation>
      </ref>
      <ref id="R4">
        <label>4.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gastaut</surname><given-names>JL</given-names></name><name><surname>Bartolomei</surname><given-names>F</given-names></name></person-group>
<article-title>Mills' syndrome: ascending (or descending) progressive hemiplegia: a hemiplegic form of primary lateral sclerosis?</article-title>
<source>J Neurol Neurosurg Psychiatry</source>
<year>1994</year>;<volume>57</volume>:<fpage>1280</fpage>&#x2013;<lpage>1281</lpage><pub-id pub-id-type="pmid">7931406</pub-id></mixed-citation>
      </ref>
      <ref id="R5">
        <label>5.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mesulam</surname><given-names>MM</given-names></name></person-group>
<article-title>Slowly progressive aphasia without generalized dementia</article-title>. <source>Ann Neurol</source>
<year>1982</year>;<volume>11</volume>:<fpage>592</fpage>&#x2013;<lpage>598</lpage><pub-id pub-id-type="pmid">7114808</pub-id></mixed-citation>
      </ref>
      <ref id="R6">
        <label>6.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidtke</surname><given-names>K</given-names></name><name><surname>Hiersemenzel</surname><given-names>LP</given-names></name></person-group>
<article-title>Progressive hemiparesis in frontal lobe degeneration</article-title>. <source>Eur Neurol</source>
<year>1997</year>;<volume>38</volume>:<fpage>105</fpage>&#x2013;<lpage>112</lpage><pub-id pub-id-type="pmid">9286633</pub-id></mixed-citation>
      </ref>
      <ref id="R7">
        <label>7.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuchiya</surname><given-names>K</given-names></name><name><surname>Ozawa</surname><given-names>E</given-names></name><name><surname>Fukushima</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Rapidly progressive aphasia and motor neuron disease: a clinical, radiological, and pathological study of an autopsy case with circumscribed lobar atrophy</article-title>. <source>Acta Neuropathol</source>
<year>2000</year>;<volume>99</volume>:<fpage>81</fpage>&#x2013;<lpage>87</lpage><pub-id pub-id-type="pmid">10651032</pub-id></mixed-citation>
      </ref>
      <ref id="R8">
        <label>8.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Seo</surname><given-names>SW</given-names></name><name><surname>Go</surname><given-names>SM</given-names></name><etal/></person-group>
<article-title>Semantic dementia combined with motor neuron disease</article-title>. <source>J Clin Neurosci</source>
<year>2009</year>;<volume>16</volume>:<fpage>1683</fpage>&#x2013;<lpage>1685</lpage><pub-id pub-id-type="pmid">19800241</pub-id></mixed-citation>
      </ref>
      <ref id="R9">
        <label>9.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>MR</given-names></name><name><surname>Gerhard</surname><given-names>A</given-names></name><name><surname>Al-Chalabi</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Mills' and other isolated upper motor neuron syndromes: In vivo study with [11C]-PK11195 PET</article-title>. <source>J Neurol Neurosurg Psychiatry</source>
<year>2005</year>;<volume>76</volume>:<fpage>871</fpage>&#x2013;<lpage>874</lpage><pub-id pub-id-type="pmid">15897516</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
